

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Review Proposal Project

### NICE Technology Appraisal No.410; Talimogene laherparepvec for treating unresectable metastatic melanoma

#### Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> <li>• Amgen</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Black Health Agency</li> <li>• British Skin Foundation</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer52</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie</li> <li>• Melanoma UK</li> <li>• Muslim Council of Britain</li> <li>• OcuMel UK</li> <li>• Skcin - Karen Clifford Skin Cancer Charity</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus Cancer Care</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Anaesthetists of Great Britain and Ireland</li> <li>• Association of Cancer Physicians</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association of Dermatologists</li> <li>• British Association of Skin Cancer Specialist Nurses</li> <li>• British Association of Surgical Oncology</li> <li>• British Dermatological Nursing Group</li> <li>• British Geriatrics Society</li> </ul>	<p><u>General commentators</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparators</u></p> <ul style="list-style-type: none"> <li>• Bristol-Myers Squibb Pharmaceutical (ipilimumab)</li> <li>• Novartis (dabrafenib)</li> <li>• Roche Products (vemurafenib)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Society for Dermatological Surgery</li> <li>• Cochrane Skin Group</li> <li>• Institute of Cancer Research</li> <li>• Melanoma Fund</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> <li>• Skin Cancer Research Fund</li> <li>• Skin Treatment &amp; Research Trust</li> </ul>

<ul style="list-style-type: none"> <li>• British Institute of Radiology</li> <li>• British Psychosocial Oncology Society</li> <li>• Cancer Research UK</li> <li>• Melanoma Focus</li> <li>• Primary Care Dermatology Society</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS Barnsley CCG</li> <li>• NHS England</li> <li>• NHS Windsor, Ascot and Maidenhead CCG</li> <li>• Welsh Government</li> </ul>	<p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>
---	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

**PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS**

## Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

## Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.